Early onset and liver failure indicating poor prognosis of infant liver failure syndrome type 1.
LARS1
Acute liver failure
Genotype
Leucyl-tRNA synthase 1
Survival analysis
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
06 Jun 2024
06 Jun 2024
Historique:
received:
25
10
2023
accepted:
27
05
2024
medline:
7
6
2024
pubmed:
7
6
2024
entrez:
6
6
2024
Statut:
epublish
Résumé
Infantile liver failure syndrome type 1 (ILFS1, OMIM #615,438), caused by leucyl-tRNA synthase 1 (LARS1, OMIM *151,350) deficiency, is a rare autosomal-recessive disorder. The clinical manifestations, molecular-genetic features, and prognosis of LARS1 disease remain largely elusive. Three new instances of ILFS1 with confirmed variants in LARS1, encoding LARS1, were identified. Disease characteristics were summarized together with those of 33 reported cases. Kaplan-Meier analysis was performed to assess prognostic factors in ILFS1 patients. The 3 new ILFS1 patients harbored 6 novel variants in LARS1. Among the 36 known patients, 12 died or underwent liver transplantation. The main clinical features of ILFS1 were intrauterine growth restriction (31/32 patients in whom this finding was specifically described), failure to thrive (30/31), hypoalbuminemia (32/32), microcytic anemia (32/33), acute liver failure (24/34), neurodevelopmental delay (25/30), seizures (22/29), and muscular hypotonia (13/27). No significant correlations were observed between genotype and either presence of liver failure or clinical severity of disease. Kaplan-Meier analysis indicated that age of onset < 3mo (p = 0.0015, hazard ratio = 12.29, 95% confidence interval [CI] = 3.74-40.3), like liver failure (p = 0.0343, hazard ratio = 6.57, 95% CI = 1.96-22.0), conferred poor prognosis. Early age of presentation, like liver failure, confers poor prognosis in ILFS1. Genotype-phenotype correlations remain to be established.
Sections du résumé
BACKGROUND
BACKGROUND
Infantile liver failure syndrome type 1 (ILFS1, OMIM #615,438), caused by leucyl-tRNA synthase 1 (LARS1, OMIM *151,350) deficiency, is a rare autosomal-recessive disorder. The clinical manifestations, molecular-genetic features, and prognosis of LARS1 disease remain largely elusive.
METHODS
METHODS
Three new instances of ILFS1 with confirmed variants in LARS1, encoding LARS1, were identified. Disease characteristics were summarized together with those of 33 reported cases. Kaplan-Meier analysis was performed to assess prognostic factors in ILFS1 patients.
RESULTS
RESULTS
The 3 new ILFS1 patients harbored 6 novel variants in LARS1. Among the 36 known patients, 12 died or underwent liver transplantation. The main clinical features of ILFS1 were intrauterine growth restriction (31/32 patients in whom this finding was specifically described), failure to thrive (30/31), hypoalbuminemia (32/32), microcytic anemia (32/33), acute liver failure (24/34), neurodevelopmental delay (25/30), seizures (22/29), and muscular hypotonia (13/27). No significant correlations were observed between genotype and either presence of liver failure or clinical severity of disease. Kaplan-Meier analysis indicated that age of onset < 3mo (p = 0.0015, hazard ratio = 12.29, 95% confidence interval [CI] = 3.74-40.3), like liver failure (p = 0.0343, hazard ratio = 6.57, 95% CI = 1.96-22.0), conferred poor prognosis.
CONCLUSIONS
CONCLUSIONS
Early age of presentation, like liver failure, confers poor prognosis in ILFS1. Genotype-phenotype correlations remain to be established.
Identifiants
pubmed: 38844943
doi: 10.1186/s13023-024-03229-3
pii: 10.1186/s13023-024-03229-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
225Subventions
Organisme : National Natural Science Foundation of China
ID : 82201898
Organisme : Health Industry Clinical Research Project of Shanghai Municipal Health Commission
ID : 20224Y0281
Informations de copyright
© 2024. The Author(s).
Références
Casey JP, McGettigan P, Lynam-Lennon N, McDermott M, Regan R, Conroy J, et al. Identification of a mutation in LARS as a novel cause of infantile hepatopathy. Mol Genet Metab. 2012;106(3):351–8. https://doi.org/10.1016/j.ymgme.2012.04.017 .
doi: 10.1016/j.ymgme.2012.04.017
pubmed: 22607940
Han JM, Jeong SJ, Park MC, Kim G, Kwon NH, Kim HK, et al. Leucyl-tRNA synthetase is an intracellular leucine sensor for the mTORC1-signaling pathway. Cell. 2012;149(2):410–24. https://doi.org/10.1016/j.cell.2012.02.044 .
doi: 10.1016/j.cell.2012.02.044
pubmed: 22424946
Tabolacci E, Molinario C, Marangi G, Nobile V, Arena V, Mendes MI, et al. Infantile liver failure syndrome 1 associated with a novel variant of the LARS1 gene: clinical, genetic, and functional characterization. Clin Genet. 2021;99(4):601–3. https://doi.org/10.1111/cge.13893 .
doi: 10.1111/cge.13893
pubmed: 33314043
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24. https://doi.org/10.1038/gim.2015.30 .
doi: 10.1038/gim.2015.30
pubmed: 25741868
pmcid: 4544753
Lenz D, Smith DEC, Crushell E, Husain RA, Salomons GS, Alhaddad B, et al. Genotypic diversity and phenotypic spectrum of infantile liver failure syndrome type 1 due to variants in LARS1. Genet Med. 2020;22(11):1863–73. https://doi.org/10.1038/s41436-020-0904-4 .
doi: 10.1038/s41436-020-0904-4
pubmed: 32699352
Lin WX, Zheng QQ, Guo L, Cheng Y, Song YZ. Clinical feature and molecular diagnostic analysis of the first noncaucasian child with infantile liver failure syndrome type 1. Chin J Contemp Pediatr. 2017;19(8):913–20. https://doi.org/10.7499/j.issn.1008-8830.2017.08.013 .
doi: 10.7499/j.issn.1008-8830.2017.08.013
Peroutka C, Salas J, Britton J, Bishop J, Kratz L, Gilmore MM, et al. Severe neonatal manifestations of infantile liver failure syndrome type 1 caused by cytosolic leucine-tRNA synthetase deficiency. J Inherit Metab Dis. 2019;45:71–6. https://doi.org/10.1007/8904_2018_143 .
doi: 10.1007/8904_2018_143
Fuchs SA, Schene IF, Kok G, Jansen JM, Nikkels PGJ, van Gassen KLI, et al. Aminoacyl-tRNA synthetase deficiencies in search of common themes. Genet Med. 2019;21(2):319–30. https://doi.org/10.1038/s41436-018-0048-y .
doi: 10.1038/s41436-018-0048-y
pubmed: 29875423
Xinli B, Tingting Y, Xiaolan Z, Shuzhen M, Yingchao L. Clinical and genetic characteristics of a family with infantile liver failure syndrome type 1. Chin J Appl Clin Pediatr. 2019;34(7):552–4. https://doi.org/10.3760/cma.j.issn.2095-428X.2019.07.019 .
doi: 10.3760/cma.j.issn.2095-428X.2019.07.019
Abstracts of the 33rd Annual Conference of the Arbeitsgemeinschaft für Pädiatrische Stoffwechselstörungen (APS) (Association for pediatric metabolic disorders). Monatsschr Kinderh. 2019;167:359–76. https://doi.org/10.1007/s00112-019-0665-9 .
Hirata K, Okamoto N, Ichikawa C, Inoue S, Nozaki M, Banno K, et al. Severe course with lethal hepatocellular injury and skeletal muscular dysgenesis in a neonate with infantile liver failure syndrome type 1 caused by novel LARS1 mutations. Am J Med Genet A. 2021;185(3):866–70. https://doi.org/10.1002/ajmg.a.62012 .
doi: 10.1002/ajmg.a.62012
pubmed: 33300650
Pan L, Xiaoguai L, Xiaokang P, Ruina L, Lingxia L, Yarong L. A case report of infantile liver failure syndrome type 1. Chin J Evid Based Pediatr. 2020;15(1):76–80. https://doi.org/10.3969/j.issn.1673-5501.2020.01.018 .
doi: 10.3969/j.issn.1673-5501.2020.01.018
Pan L, Xiaoguai L, Xiaokang P, Ruina L, Lingxia L, Yarong L, et al. Deep phenotyping of MARS1 (interstitial lung and liver disease) and LARS1 (infantile liver failure syndrome 1) recessive multisystemic disease using Human Phenotype Ontology annotation: Overlap and differences. Case report and review of literature. Eur J Med Genet. 2021;64(11):104334. https://doi.org/10.1016/j.ejmg.2021.104334
doi: 10.1016/j.ejmg.2021.104334
Hegarty R, Gibson P, Sambrotta M, Strautnieks S, Foskett P, Ellard S, et al. Study of acute liver failure in children using next generation sequencing technology. J Pediatr. 2021;236:124–30. https://doi.org/10.1016/j.jpeds.2021.05.041 .
doi: 10.1016/j.jpeds.2021.05.041
pubmed: 34023347
Hegarty R, Gibson P, Sambrotta M, Strautnieks S, Foskett P, Ellard S. Familial infantile liver failure syndrome 1: novel LARS1 gene mutation. Indian J Pediatr. 2022;89(9):922. https://doi.org/10.1007/s12098-022-04249-2 .
doi: 10.1007/s12098-022-04249-2
Casey JP, Slattery S, Cotter M, Monavari AA, Knerr I, Hughes J, et al. Clinical and genetic characterisation of infantile liver failure syndrome type 1, due to recessive mutations in LARS. J Inherit Metab Dis. 2015;38(6):1085–92. https://doi.org/10.1007/s10545-015-9849-1 .
doi: 10.1007/s10545-015-9849-1
pubmed: 25917789